{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:11:12Z","timestamp":1785762672356,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Bei kritisch Kranken besteht ein hohes Risko f\u00fcr unerw\u00fcnschte Arzneimittelinteraktionen. Pharmakodynamische Interaktionen k\u00f6nnen Organtoxizit\u00e4t verst\u00e4rken. Pharmakokinetische Interaktionen gr\u00fcnden meist auf einer Hemmung oder Induktion von Enzymen des Arzneimittelmetabolismus wie Cytochrom-P-450-Isoenzymen und Transporterproteinen wie P\u2011Glykoprotein. Inhibitoren dieser Molek\u00fcle k\u00f6nnen so toxische Wirkspiegel der entsprechenden Substrate herbeif\u00fchren, Induktoren hingegen subtherapeutische Konzentrationen. Amiodaron, Makrolide, Azol-Antimykotika, direkt wirksame Antikoagulanzien, Vitamin-K-Antagonisten, Immunsuppressiva, Rifampicin und einige ZNS-wirksame Substanzen sind besonders h\u00e4ufig an Interaktionen beteiligt. Eine \u00dcberpr\u00fcfung der Medikation unter strenger Risiko-Nutzen-Abw\u00e4gung, therapeutisches Drugmonitoring, Verwendung elektronischer Alert-Systeme und Datenbanken zusammen mit klinischer Bewertung k\u00f6nnen zur Vermeidung unerw\u00fcnschter Arzneimittelinteraktionen beitragen.<\/jats:p>","DOI":"10.1007\/s00063-024-01214-z","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:43:15Z","timestamp":1732786995000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Arzneimittelinteraktionen bei kritisch Kranken","Drug\u2013drug interactions in critically ill patients"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-3258","authenticated-orcid":false,"given":"Romuald","family":"Bellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcrc.2020.11.020","volume":"62","author":"T Bakker","year":"2021","unstructured":"Bakker\u00a0T, Abu-Hanna\u00a0A, Dongelmans\u00a0DA et\u00a0al (2021) Clinically relevant potential drug-drug interactions in intensive care patients: A\u00a0large retrospective observational multicenter study. J\u00a0Crit Care 62:124\u2013130","journal-title":"J Crit Care"},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/jcph.2020","volume":"62","author":"T Bakker","year":"2022","unstructured":"Bakker\u00a0T, Dongelmans\u00a0DA, Nabovati\u00a0E et\u00a0al (2022) Heterogeneity in the Identification of Potential Drug-Drug Interactions in the Intensive Care Unit: A\u00a0Systematic Review, Critical Appraisal, and Reporting Recommendations. J\u00a0Clin Pharmacol 62:706\u2013720","journal-title":"J Clin Pharmacol"},{"key":"1214_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0140-6736(23)02465-0","volume":"403","author":"T Bakker","year":"2024","unstructured":"Bakker\u00a0T, Klopotowska\u00a0JE, Dongelmans\u00a0DA et\u00a0al (2024) The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a\u00a0cluster randomised stepped-wedge trial. Lancet 403:439\u2013449","journal-title":"Lancet"},{"key":"1214_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00063-017-0284-y","volume":"112","author":"R Bellmann","year":"2017","unstructured":"Bellmann\u00a0R (2017) Personalisierte Pharmakotherapie beim Intensivpatienten. Med Klin Intensivmed Notfmed 112:289\u2013294","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1214_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00063-013-0308-1","volume":"109","author":"R Bellmann","year":"2014","unstructured":"Bellmann\u00a0R (2014) Pharmakokinetische und pharmakodynamische Aspekte bei der Antibiotikatherapie. Med Klin Intensivmed Notfmed 109:162\u2013166","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1214_CR6","first-page":"3","volume":"8","author":"R Bellmann","year":"2013","unstructured":"Bellmann\u00a0R (2013) Pharmacokinetic and pharmacodynamic considerations in the treatment of severe infections. Curr Clin Pharmacol 8:3\u20134","journal-title":"Curr Clin Pharmacol"},{"key":"1214_CR7","doi-asserted-by":"crossref","unstructured":"Bellmann R, Smuszkiewicz P (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection","DOI":"10.1007\/s15010-017-1042-z"},{"key":"1214_CR8","doi-asserted-by":"crossref","unstructured":"Bourdin V, Bigot W, Vanjak A et\u00a0al (2023) Drug-Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? J\u00a0Clin Med 12:","DOI":"10.3390\/jcm12227120"},{"key":"1214_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer\u00a0EW, Shannon\u00a0M (2005) The serotonin syndrome. N\u00a0Engl J Med 352:1112\u20131120","journal-title":"N Engl J Med"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"809393","DOI":"10.3389\/fmed.2022.809393","volume":"9","author":"I Budic","year":"2022","unstructured":"Budic\u00a0I, Jevtovic Stoimenov\u00a0T, Pavlovic\u00a0D et\u00a0al (2022) Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics. Front Med 9:809393","journal-title":"Front Med"},{"key":"1214_CR11","doi-asserted-by":"crossref","unstructured":"Cattaneo D, Gervasoni C, Corona A (2022) The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A\u00a0Narrative Review. Antibiotics 11:","DOI":"10.3390\/antibiotics11101410"},{"key":"1214_CR12","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","volume":"37","author":"G Choi","year":"2009","unstructured":"Choi\u00a0G, Gomersall\u00a0CD, Tian\u00a0Q et\u00a0al (2009) Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37:2268\u20132282","journal-title":"Crit Care Med"},{"key":"1214_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/a-0903-1767","volume":"55","author":"A Drust","year":"2020","unstructured":"Drust\u00a0A (2020) Arzneimittelinteraktionen in der Intensivmedizin. An\u00e4sthesiol Intensivmed Notfallmed Schmerzther 55:300\u2013313","journal-title":"An\u00e4sthesiol Intensivmed Notfallmed Schmerzther"},{"key":"1214_CR14","volume-title":"Diagnosia Enterprise","author":"Ebewe","year":"2024","unstructured":"Ebewe (2024) Amiodaron, Fachinformation. In: Diagnosia Enterprise. Diagnosia,"},{"key":"1214_CR15","volume-title":"Critical Care Toxicoloy","author":"B Farmer","year":"2017","unstructured":"Farmer\u00a0B, Yip\u00a0L (2017) Medication errors and drug-drug interactions in the intensive care unit. In: Critical Care Toxicoloy. Spriner Nature,"},{"key":"1214_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/17425255.2021.1902985","volume":"17","author":"M Fiore","year":"2021","unstructured":"Fiore\u00a0M, Peluso\u00a0L, Taccone\u00a0FS et\u00a0al (2021) The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients. Expert Opin Drug Metab Toxicol 17:543\u2013554","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1214_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40264-019-00829-y","volume":"42","author":"MG Fitzmaurice","year":"2019","unstructured":"Fitzmaurice\u00a0MG, Wong\u00a0A, Akerberg\u00a0H et\u00a0al (2019) Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A\u00a0Systematic Review and Meta-Analysis. Drug Saf 42:1035\u20131044","journal-title":"Drug Saf"},{"key":"1214_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-021-01040-y","volume":"60","author":"M Gatti","year":"2021","unstructured":"Gatti\u00a0M, Pea\u00a0F (2021) Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A\u00a0Practical Approach for Guiding Dose Optimization of Novel Antibiotics. Clin Pharmacokinet 60:1271\u20131289","journal-title":"Clin Pharmacokinet"},{"key":"1214_CR19","volume-title":"Veklury, Fachinformation","author":"Gilead","year":"2014","unstructured":"Gilead (2014) Veklury, Fachinformation. Diagnosia"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jth.13614","volume":"15","author":"J Holm","year":"2017","unstructured":"Holm\u00a0J, Lindh\u00a0JD, Andersson\u00a0ML et\u00a0al (2017) The effect of amiodarone on warfarin anticoagulation: a\u00a0register-based nationwide cohort study involving the Swedish population. J\u00a0Thromb Haemost 15:446\u2013453","journal-title":"J Thromb Haemost"},{"key":"1214_CR21","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1097\/CCM.0000000000002533","volume":"45","author":"SL Kane-Gill","year":"2017","unstructured":"Kane-Gill\u00a0SL, Dasta\u00a0JF, Buckley\u00a0MS et\u00a0al (2017) Clinical Practice Guideline: Safe Medication Use in the ICU. Crit Care Med 45:e877\u2013e915","journal-title":"Crit Care Med"},{"key":"1214_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1074248414529622","volume":"19","author":"DH Katz","year":"2014","unstructured":"Katz\u00a0DH, Intwala\u00a0SS, Stone\u00a0NJ (2014) Addressing statin adverse effects in the clinic: the 5 Ms. J\u00a0Cardiovasc Pharmacol Ther 19:533\u2013542","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1214_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bcp.15882","volume":"90","author":"JE Klopotowska","year":"2024","unstructured":"Klopotowska\u00a0JE, Leopold\u00a0JH, Bakker\u00a0T et\u00a0al (2024) Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A\u00a0multicentre retrospective observational study. Br J Clin Pharmacol 90:164\u2013175","journal-title":"Br J Clin Pharmacol"},{"key":"1214_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","volume":"24","author":"D Kuhn","year":"2020","unstructured":"Kuhn\u00a0D, Metz\u00a0C, Seiler\u00a0F et\u00a0al (2020) Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a\u00a0prospective, observational single-center study. Crit Care 24:664","journal-title":"Crit Care"},{"key":"1214_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/157488406775268183","volume":"1","author":"SE Leucuta","year":"2006","unstructured":"Leucuta\u00a0SE, Vlase\u00a0L (2006) Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 1:5\u201320","journal-title":"Curr Clin Pharmacol"},{"key":"1214_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/cid\/cix443","volume":"65","author":"M Mahmoudi","year":"2017","unstructured":"Mahmoudi\u00a0M, Brenner\u00a0T, Hatiboglu\u00a0G et\u00a0al (2017) Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a\u00a0Patient With Renal Failure. Clin Infect Dis 65:1033\u20131036","journal-title":"Clin Infect Dis"},{"key":"1214_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini\u00a0C, Kuritzkes\u00a0DR, Marra\u00a0F et\u00a0al (2022) Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther 112:1191\u20131200","journal-title":"Clin Pharmacol Ther"},{"key":"1214_CR28","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/MAT.0000000000001427","volume":"68","author":"A Mathieu","year":"2022","unstructured":"Mathieu\u00a0A, Thiboutot\u00a0Z, Ferreira\u00a0V et\u00a0al (2022) Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis: A\u00a0Case Report. ASAIO\u00a0J 68:e56\u2013e58","journal-title":"ASAIO J"},{"key":"1214_CR29","first-page":"228","volume":"74","author":"A Mourad","year":"2019","unstructured":"Mourad\u00a0A, Stiber\u00a0JA, Perfect\u00a0JR et\u00a0al (2019) Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. J\u00a0Antimicrob Chemother 74:228\u2013233","journal-title":"J Antimicrob Chemother"},{"key":"1214_CR30","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1097\/CCM.0b013e3181de0acf","volume":"38","author":"J Papadopoulos","year":"2010","unstructured":"Papadopoulos\u00a0J, Smithburger\u00a0PL (2010) Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med 38:S126\u2013135","journal-title":"Crit Care Med"},{"key":"1214_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11239-021-02561-w","volume":"53","author":"N Potere","year":"2022","unstructured":"Potere\u00a0N, Candeloro\u00a0M, Porreca\u00a0E et\u00a0al (2022) Direct oral anticoagulant plasma levels in hospitalized COVID-19\u00a0patients treated with dexamethasone. J\u00a0Thromb Thrombolysis 53:346\u2013351","journal-title":"J Thromb Thrombolysis"},{"key":"1214_CR32","first-page":"290","volume":"46","author":"P Riera","year":"2022","unstructured":"Riera\u00a0P, Sole\u00a0N, Suarez\u00a0JC et\u00a0al (2022) Drug-drug interactions in an intensive care unit and comparison of updates in two databases. Farm Hosp 46:290\u2013295","journal-title":"Farm Hosp"},{"key":"1214_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10840-022-01355-1","volume":"66","author":"M Shurrab","year":"2023","unstructured":"Shurrab\u00a0M, Jackevicius\u00a0CA, Austin\u00a0PC et\u00a0al (2023) Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients. J\u00a0Interv Card Electrophysiol 66:629\u2013635","journal-title":"J Interv Card Electrophysiol"},{"key":"1214_CR34","first-page":"e30383","volume":"14","author":"A Singh","year":"2022","unstructured":"Singh\u00a0A, Anjankar\u00a0AP (2022) Propofol-Related Infusion Syndrome: A\u00a0Clinical Review. Cureus 14:e30383","journal-title":"Cureus"},{"key":"1214_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel\u00a0J, Verhamme\u00a0P, Potpara\u00a0TS et\u00a0al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin\u00a0K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart\u00a0J 39:1330\u20131393","journal-title":"Eur Heart J"},{"key":"1214_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2015.06.081","volume":"201","author":"C Stollberger","year":"2015","unstructured":"Stollberger\u00a0C, Bastovansky\u00a0A, Finsterer\u00a0J (2015) Fatal intracerebral bleeding under rivaroxaban. Int J Cardiol 201:110\u2013112","journal-title":"Int J Cardiol"},{"key":"1214_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/phar.1395","volume":"34","author":"EV Uijtendaal","year":"2014","unstructured":"Uijtendaal\u00a0EV, Van Harssel\u00a0LL, Hugenholtz\u00a0GW et\u00a0al (2014) Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy 34:213\u2013219","journal-title":"Pharmacotherapy"},{"key":"1214_CR38","first-page":"e46497","volume":"15","author":"S Van","year":"2023","unstructured":"Van\u00a0S, Lam\u00a0V, Patel\u00a0K et\u00a0al (2023) Propofol-Related Infusion Syndrome: A\u00a0Bibliometric Analysis of the 100 Most-Cited Articles. Cureus 15:e46497","journal-title":"Cureus"},{"key":"1214_CR39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/bmjqs-2017-007531","volume":"27","author":"A Wong","year":"2018","unstructured":"Wong\u00a0A, Amato\u00a0MG, Seger\u00a0DL et\u00a0al (2018) Prospective evaluation of medication-related clinical decision support over-rides in the intensive care unit. BMJ Qual Saf 27:718\u2013724","journal-title":"BMJ Qual Saf"},{"key":"1214_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jcrc.2017.02.027","volume":"39","author":"A Wong","year":"2017","unstructured":"Wong\u00a0A, Amato\u00a0MG, Seger\u00a0DL et\u00a0al (2017) Evaluation of medication-related clinical decision support alert overrides in the intensive care unit. J\u00a0Crit Care 39:156\u2013161","journal-title":"J Crit Care"},{"key":"1214_CR41","unstructured":"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S0140673623024650-mmc1.pdf"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-024-01214-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-024-01214-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-024-01214-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:15:27Z","timestamp":1762524927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-024-01214-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s00063-024-01214-z","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Bellmann erhielt F\u00f6rdermittel von FWF Grant (\u00f6sterreichischer Wissenschaftsfonds), IIR Grant von Pfizer, IIR Grant von Rokitan, Wien; ist Mitarbeiter bei Advisory Boards: Merck Sharp & Dohme, Pfizer und Mundipharma. S.\u00a0Weiler: CoFounder, Methodds GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}